The largest database of trusted experimental protocols

Eclipse software

Manufactured by Agilent Technologies
Sourced in United States

Eclipse software is a core component of Agilent Technologies' analytical instrumentation. It provides a user interface and control for various laboratory equipment and technologies developed by Agilent.

Automatically generated - may contain errors

11 protocols using eclipse software

1

VMAT Optimization and Dose Calculation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single and double full‐arc VMAT plans were generated for each patient using the TrueBeam STx system (Varian) operating the Eclipse software (ver. 13.7.29; Varian). The collimator angle was set to 30° for the single‐arc plans and ± 30° for the double arc plans. The TrueBeam STx was equipped with a high‐definition 120 MLC with a central leaf width of 2.5 mm. The nominal energy and maximum dose rate were 10‐MV flattened photon beams and 600 MU/min, respectively. Dose calculation was performed using the Acuros XB system (ver. 13.7.14; Varian), with a grid size of 2.5 mm for the mid‐ventilation phase of 4DCT. A dose of 50.4 Gy in 28 fractions was prescribed to cover 50% of the PTV. Dose‐volume constraints for each organ are shown in Table 1. The calculated dose distributions were labeled “3D plans”.
After dose calculation, one Digital Imaging and Communications in Medicine–Radiation Therapy (DICOM‐RT) plan file was obtained for each plan. This original DICOM‐RT plan file contained 178 control points (CPs) that represented the beam delivery parameters, including gantry angles, MLC positions, dose rates, and MUs per degree of gantry rotation at approximately 2° gantry angle intervals for each arc.
+ Open protocol
+ Expand
2

Nasopharyngeal Cancer Staging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients were staged with nasopharyngeal CT scan or nasopharyngeal MRI with contrast agent, chest X-Ray, abdominal ultrasound, and bone scan. The nasopharyngeal CT Scan or MRI images was always obtained from frontal sinus until lower neck. The staging used was based on American Joint Committee on Cancer (AJCC) version 8. The nasopharyngeal CT scan or nasopharyngeal MRI which was conducted within 1-month time from the date of nasopharyngeal biopsy was used as the basis of tumor volume determination.
The tumor volume was measured separately between primary tumor and neck nodes. The tumor volume based on nasopharyngeal CT scan or MRI was delineated by an experienced radiation oncologist with Eclipse software from Varian. The primary nasopharyngeal tumor volume was denoted GTVp, while the nodal tumor volume was denoted GTVn.
+ Open protocol
+ Expand
3

Interobserver Variability in GTV Delineation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gross tumor volume (GTV) was contoured on CT images using Eclipse software (Varian Medical Systems, Palo Alto, CA, USA) by one of three board-certified radiation oncologists, specializing in head-and-neck cancer, with varying levels of experience (19, 8, and 4 years post board certification). To facilitate the CT-MR image alignment, the region of interest (ROI) encompassing the GTV on CT was mapped to the corresponding MR images using 3D-slicer software version 4.11. The mapping process involved identifying anatomical landmarks on both the CT and MR images, as well as utilizing the registration location produced during the radiation oncologist’s treatment planning process to ensure accurate registration. The resulting MR images with the mapped ROI were then used for further analysis.
To assess for interobserver variability, we randomly sampled 22 patients out of the total sample size. For each of these 22 patients, the GTV was independently contoured by the other two board-certified radiation oncologists who were blinded to each other and the original GTV contours. These additional radiation oncologists utilized the same imaging software and datasets as the primary radiation oncologist who initially contoured the GTV.
+ Open protocol
+ Expand
4

Lung and Heart Dose Constraints in RT

Check if the same lab product or an alternative is used in the 5 most similar protocols
All treatment plans had to match intradepartmental dose constraints and were identically standardized using the PTV. Dose–volume parameters were expressed as (1) percentage of the volume of an OAR receiving a certain dose (VxxGy), (2) mean and maximum dose in Gy received by a certain OAR (Dmean and Dmax), or 3) dose in Gy received by a certain percentage of the volume (Dxx%).
The applied dose constraints for the lungs were as follows: V20Gy < 30%, V30Gy < 20%, and V20Gy < 1000 mL. The dose constraint for the spinal cord was Dmax < 47 Gy, and for the esophagus was Dmax < 74 Gy. The dose constraints used for the heart were: Dmean < 35 Gy, D33% < 60 Gy, and D50% < 45 Gy. The treatment plans were calculated using an anisotropic analytical algorithm (AAA) in Eclipse software™ (Varian Medical Systems, Inc., Palo Alto, CA, USA).
For our analyses, the following dose–volume parameters were analyzed: lung Dmean, V5Gy–V60Gy in 5 Gy steps, as well as heart Dmean, D33%, and D50%. Furthermore, the GTV and PTV volumes in mL were analyzed.
+ Open protocol
+ Expand
5

SBRT and Immunotherapy for Spinal Metastases

Check if the same lab product or an alternative is used in the 5 most similar protocols
An institutional review board–approved retrospective review was carried out on all patients treated with SBRT for a spinal (C1-S5) metastasis and who had systemic therapy data available from 2010 to 2019. IT was defined as any targeted agent with a primary mechanism of action designed to enhance immunologic activity against malignancy. SBRT was defined as a treatment using ≤5 fractions and a dose of at least 6 Gy/fraction. The electronic medical record was used to obtain patient characteristics and dates of SBRT and IT administration.
Treatment was delivered using a TrueBeam (Varian Medical Systems, Palo Alto, CA) platform with either 1 or 3 fractions. Targets were visualized using computed tomography simulation in conjunction with high-resolution magnetic resonance imaging with T1- and T2-weighted sequences. The gross tumor volume, clinical tumor volume, and planning treatment volume were contoured in accordance with consensus guidelines.4 ,32 (link) Treatment plans were generated using Eclipse software (Varian Medical Systems). Maximum dose to the spinal cord was limited to 14 Gy for single-fraction treatments and 21.9 Gy for 3-fraction treatments in accordance with published guidelines.32 (link),33 (link) Patients underwent a clinical evaluation and magnetic resonance imaging every 3 months for 1 year and then follow-up intervals increased to every 6 months.
+ Open protocol
+ Expand
6

Standardized CT Tumor Segmentation

Check if the same lab product or an alternative is used in the 5 most similar protocols
CTs were acquired according to standardized scanning protocols at our institution using a GE “Lightspeed” CT scanner (GE Medical System, Milwaukee, WI, USA) for treatment planning. Tumor segmentation was performed on radiation therapy planning CTs using Eclipse software (Varian Medical System, Palo Alto, CA, USA). The primary tumor site and lymph nodes were contoured using both soft tissue and lung windows by the treating radiation oncologists. Air, vessels, normal tissue or surrounding organs were subsequently excluded from these contours, and then individually verified by an expert radiation oncologist. If a patient presented with more than one clinically positive nodal station, the union of all the stations was analyzed.
+ Open protocol
+ Expand
7

4D-CT and Contrast-enhanced Planning for Radiotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
Planning CT was acquired as 4D-CT with retrospective amplitude-based image sorting. In addition, a 3D-CT was performed in free breathing to allow for contrast i.v. injection.
Gross tumor volume (GTV) was contoured as the visible tumor in the planning CT supplemented by information from i.v. contrast 3D-CT or further imaging including FDG-PET or magnetic resonance imaging (MRI) if available. In FDG-PET CT scans, the FDG active lesions with an visible correlate in the i.v. CT scans were contoured. No additional clinical target volume (CTV) margin was added (i.e., GTV = CTV).
The internal target volume (ITV) was generated as a composite GTV from the different amplitude-based reconstructed CT scans complemented by a margin of 5 mm to derive the planning target volume (PTV). Treatment planning and delivery was done with either conformal or intensity-modulated (VMAT) techniques.
All plans were calculated by a radiation therapy technologist using common constraints for the organs at risk and target prescription standards and were multidisciplinary reviewed. For treatment planning, Eclipse software™ (Varian medical systems) was used. Patients were treated with either 6 or 18 MV. If necessary immobilization by individualized vacuum cast or abdominal compression was used.
+ Open protocol
+ Expand
8

Simultaneous PET/MRI for Prostate Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole-body and dedicated regional PET/MRI images of the prostate were acquired on a GE SIGNA 3.0 Tesla PET/MRI scanner. Whole-body magnetic resonance sequences included axial T1 fat-saturated, sagittal T1 non–fat saturated, and T2 weighted images. PET/MRI acquisition was simultaneous and included a total of 6 bed positions with 5-minute PET acquisition per bed position. The dedicated prostate PET/MRI protocol was performed per institutional protocol and included the essential components of multiparametric prostate MRI: diffusion-weighted images (up to b2000), small field-of-view T2-weighted images (axial, sagittal, and coronal), and dynamic contrast-enhanced images of the prostate gland. A delayed regional PET acquisition was performed during acquisition of the prostate MRI. The PET/MRI images were analyzed using MIM (Cleveland, OH), and the PET/MRI scans were extracted to DICOM files for integration into the Varian Eclipse software.
+ Open protocol
+ Expand
9

CT Slice Thickness Impact on Tumor Tracking

Check if the same lab product or an alternative is used in the 5 most similar protocols
The effect of CT slice thickness on template quality and therefore
MTT performance was evaluated using a fixed angle fast-kV switching
projections obtained for all five simulated tumors at an oblique angle of
45°. To generate templates, the CIRS phantom was scanned on the
Siemens SOMATOM Open AS (Siemens Healthineers, Forchheim, Germany). These
images were subsequently contoured using the Eclipse software (Varian, Palo
Alto, CA) by a trained physicist and the contours then were used to generate
templates for tracking software using non-commercial RapidTrack-Planning
software (RTP version 1.12.2, Varian Medical Systems). To evaluate the
impact of the CT slice thickness on template generation, these images were
reconstructed using 0.75, 1.0, 1.5, 2.0 and 3.0 mm slice thicknesses. For
both DE and SE image sequences, MTT was evaluated for each tumor size/CT
slice thickness combination.
+ Open protocol
+ Expand
10

4D CT Imaging of Lung Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients had both FB and 4D CT scans acquired on a GE LightSpeed RT16 CT scanner (GE Medical Systems, Milwaukee, WI, USA) according to standard clinical scanning protocols. The most common imaging slice thickness and pixel spacing was 2.5 mm and 1.27 mm by 1.27 mm, respectively. All FB and AIP images were acquired with 120 kVp, and a standard reconstruction convolution kernel. AIP images were reconstructed from 4D CT image datasets that were acquired in axial cine mode, corresponding to one breathing cycle. The primary tumor site was manually contoured on FB and AIP images by E.H., V.A., and Y.H. on Eclipse software (Varian Medical Systems, Palo Alto, CA, USA), and then individually verified by an expert radiation oncologist (R.H.M.).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!